Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnerships
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnerships
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > News > Wake-up call to offer equal access to life-prolonging treatments in metastatic prostate cancer
  • News

Wake-up call to offer equal access to life-prolonging treatments in metastatic prostate cancer

  • 3 June 2021
  • Janet Fricker
Wake-up call to offer equal access to life-prolonging treatments in metastatic prostate cancer
Total
6
Shares
6
0
0
0
0

Less than one third of men with metastatic castration-sensitive prostate cancer (mCSPC) received established treatment intensification by 2018 that had been demonstrated to extend survival. The US study evaluating real-world utilization of advanced therapies, abstract 5073, released in advance of the forthcoming ASCO meeting, taking place online June 4-8, furthermore revealed concerning data on racial disparities. Black men received markedly less intensive therapies than other racial groups.

“I’m hopeful this is a wake-up call that our patients are more often than not receiving care that has been shown to lead to inferior outcomes,” says study presenter Stephen Freeland, from Cedars-Sinai Medical Center, Los Angeles, California. The research, he adds, demonstrates a fundamental need for improving outreach education, where providers are educated about advances in life prolonging therapies.

In the past decade, the number of new treatments for mCSPC have increased dramatically. Prior to 2010, only docetaxel had been shown to extend survival. Now, several randomized controlled trials have demonstrated adding docetaxel or novel hormonal therapy (NHT, abiraterone, apalutamide, and enzalutamide) to androgen deprivation therapy (ADT) improves survival. But how are these agents being used in real world practice?

For the current study, investigators examined first-line treatment in 35,195 patients taken from a Medicare database, who had been treated between January 2009 and December 2018. Treatments were classified into four groups: androgen deprivation therapy alone (ADT), ADT plus first-generation anti-androgen therapy (AA), ADT+docetaxel, and ADT+NHT (abiraterone, apalutamide, and enzalutamide). The last two combinations have been demonstrated to improve survival.

Altogether, 35,195 men with mCSPC were included in the analysis, with a mean age of 76.5 years, of whom 78.5% were White, 11.8% Black, and 5.3% Hispanic. Overall results show, as first-line treatment, 76.4% of patients received ADT alone, 14% ADT+AA, 4.8% ADT+docetaxel, and 4.5% ADT+NHT. After the emergence of NHTs for treatment of mCSPC in 2017, treatment intensification with ADT+NHT was lower for Black than White patients. For the index year 2018 (the last year of the study) treatment was still relatively low for ADT+docetaxel and ADT+NHT across all groups, with results showing:

  • ADT+docetaxel was received by 5.3% of White non-Hispanics versus <5.7% of White Hispanics versus 4.7% of Blacks.
  • ADT+NHT was received by 16.5% of White non-Hispanics, versus 15.5‒16.5% of White Hispanics and 11.0% of Blacks.

In other malignancies, commented Freeland, similar results have been seen, where real-world practice lags behind trials demonstrating survival benefit.

Commenting on the study, Amy Rylance, Head of Improving Care at Prostate Cancer UK says, “This study highlights the time-lag between new treatments being discovered and them being made available in practice. Although it’s a US-based study, this is an issue worldwide, and it’s important that all patients – regardless of ethnicity ‒ are able to access the best treatments as soon as possible.”

Unfortunately, she adds, many men with prostate cancer (in particular older men and those with additional illnesses) are not able to tolerate chemotherapy. “That’s why we have been calling for approval of the newer treatments such as enzalutamide, abiraterone and apalutamide, which have been shown to be effective for this group of men,” she says, adding that abiraterone and enzalutamide have been temporarily approved in the UK during the Covid-19 pandemic due to the impact of chemotherapy on the immune system.

Total
6
Shares
Share 6
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • abiraterone
  • androgen deprivation therapy
  • apalutamide
  • docetaxel
  • enzalutamide
  • metastatic castration sensitive prostate cancer
  • novel hormonal therapy
  • out-reach education
  • prostate cancer
  • racial disparities
  • real-world utilization
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • News

Study provides motivation for European policy makers to implement comprehensive tobacco control

  • 31 May 2021
  • Janet Fricker
View Post
Next Article
  • Editorials

Returning to ‘normal’ and beating cancer in Europe 2021

  • 3 June 2021
  • Adriana Albini
View Post
You May Also Like
View Post
  • News

Improving outcomes in elderly patients taking multiple medications

  • Janet Fricker
  • 24 March 2023
View Post
  • News

Localised prostate cancer: active monitoring offers valid option

  • Janet Fricker
  • 24 March 2023
View Post
  • News

Radiotherapy can be safely omitted in older women with low-risk breast cancer

  • Janet Fricker
  • 10 March 2023
View Post
  • News

Plant-based diets cut risk of prostate cancer progression and recurrence by over 50%

  • Janet Fricker
  • 9 March 2023
A blood test to recognize prostate cancer
View Post
  • News

New prostate cancer blood test combining PSA with epigenetic test could reduce biopsies

  • Janet Fricker
  • 23 February 2023
View Post
  • News

Telomere shortening mediates tumour suppression

  • Janet Fricker
  • 23 February 2023
View Post
  • News

Epidemiological study sheds light on complex link between ovarian cancer and ovulation

  • Janet Fricker
  • 9 February 2023
View Post
  • News

Cancer could overtake cardiovascular disease as leading cause of death in type 2 diabetes

  • Janet Fricker
  • 9 February 2023

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Improving outcomes in elderly patients taking multiple medications
    • 24 March 2023
  • Localised prostate cancer: active monitoring offers valid option
    • 24 March 2023
  • Radiotherapy can be safely omitted in older women with low-risk breast cancer
    • 10 March 2023
  • Plant-based diets cut risk of prostate cancer progression and recurrence by over 50%
    • 9 March 2023
  • A blood test to recognize prostate cancer
    New prostate cancer blood test combining PSA with epigenetic test could reduce biopsies
    • 23 February 2023
Article
  • ‘Fragile’ cancer patients hit by Turkish earthquake need urgent support
    • 22 March 2023
  • Expert cancer surgery: could VR help speed up and standardise training?
    • 22 March 2023
  • Immunotherapy: three studies point to potential strategies to improve response
    • 10 March 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • AI in Surgery
    • 8 March 2023
  • COVID and haematological malignancies
    • 28 February 2023
  • Telemedicine Rehabilitation in the Cancer Care Continuum
    • 24 February 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnerships
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.